Genovis AB Stock Nasdaq Stockholm
Equities
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
||
- SEK | - |
Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Feb. 15 | Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2024 * | 155M 14.12M | Sales 2025 * | 238M 21.74M | Capitalization | 1.84B 168M |
---|---|---|---|---|---|
Net income 2024 * | 37M 3.38M | Net income 2025 * | 37M 3.38M | EV / Sales 2024 * | 11.1 x |
Net cash position 2024 * | 120M 10.94M | Net cash position 2025 * | 93M 8.49M | EV / Sales 2025 * | 7.32 x |
P/E ratio 2024 * |
48.9
x | P/E ratio 2025 * |
21.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.42% |
Managers | Title | Age | Since |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-12-31 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 21-12-31 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 20-05-04 | |
Director/Board Member | 63 | 18-12-31 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 13-12-31 |
1st Jan change | Capi. | |
---|---|---|
+0.80% | 12.95B | |
-7.57% | 7.84B | |
+1.97% | 5.5B | |
+0.93% | 4.61B | |
+8.48% | 4.61B | |
-49.25% | 3.4B | |
+9.21% | 2.66B | |
-14.12% | 2.08B | |
+3.45% | 1.79B |